Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.70 |
| ▸ | GAA | P10253 | 4/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.50 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | AGBL2 | Q5U5Z8 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29431167 | 1.00 | HSD17B10 (0.70) | HSD17B10GAANPSR1FFAR1FFAR4 | |
| SCHEMBL29530799 | 0.88 | HSD17B10 (0.54) | HSD17B10GAANPSR1FFAR1FFAR4 | |
| SCHEMBL14125958 | 0.88 | HSD17B10 (0.54) | HSD17B10GAANPSR1FFAR1FFAR4 | |
| SCHEMBL10864128 | 0.86 | CYP3A4 (0.62) | HSD17B10GAAFFAR1FFAR4SMN1; SMN2 | |
| SCHEMBL29598848 | 0.85 | HSD17B10 (0.53) | HSD17B10GAANPSR1FFAR1FFAR4 | |
| SCHEMBL23229170 | 0.85 | HSD17B10 (0.51) | HSD17B10FFAR1FFAR4TSHRAGBL2 | |
| SCHEMBL2445135 | 0.85 | HSD17B10 (0.51) | HSD17B10GAAFFAR1FFAR4ALDH1A1 | |
| SCHEMBL3659915 | 0.84 | HSD17B10 (0.50) | HSD17B10GAAFFAR1FFAR4SMN1; SMN2 | |
| SCHEMBL23362766 | 0.84 | SMN1; SMN2 (0.52) | HSD17B10GAAFFAR1FFAR4SMN1; SMN2 | |
| SCHEMBL3658261 | 0.84 | HSD17B10 (0.50) | HSD17B10GAAFFAR1FFAR4SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144743-A1 | COMPOUNDS | TMEM16A LIMITED (GB) | 2026-05-28 | — | — | US | disclosed |
| EP-4699655-A2 | COMPOUNDS | TMEM16A LIMITED (GB) | 2026-02-25 | — | — | EP | disclosed |
| US-12552770-B2 | Compounds for treating respiratory disease | TMEM16A LIMITED (GB) | 2026-02-17 | — | — | US | disclosed |
| US-20250340535-A1 | ALLOSTERIC EGFR INHIBITORS AND METHODS OF USE THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2025-11-06 | — | — | US | disclosed |
| US-20250340534-A1 | ALLOSTERIC EGFR INHIBITORS AND METHODS OF USE THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2025-11-06 | — | — | US | disclosed |
| US-12377105-B2 | Compounds | TMEM16A LIMITED (GB) | 2025-08-05 | — | — | US | disclosed |
| US-20240391877-A1 | COMPOUND AS INHIBITOR OF COMPLEMENT FACTOR D, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | WUHAN CREATERNA SCIENCE AND TECHNOLOGY CO.,LTD. (CN) | 2024-11-28 | — | — | US | disclosed |
| EP-4410776-A1 | COMPOUND AS INHIBITOR OF COMPLEMENT FACTOR D, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | Wuhan Createrna Science and Technology Co.,Ltd. (CN) | 2024-08-07 | — | — | EP | disclosed |
| US-20240231222-A1 | PHOTORESIST COMPOSITION AND METHOD OF FABRICATING SEMICONDUCTOR DEVICE | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2024-07-11 | — | — | US | disclosed |
| US-20240109899-A1 | BENZOFURAN COMPOUNDS AS STING AGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-04-04 | — | — | US | disclosed |
| US-20150150884-A1 | BROMODOMAIN INHIBITORS | ABBVIE INC. | 2015-06-04 | — | — | US | disclosed |
| US-8980879-B2 | Bromodomain inhibitors | ABBVIE INC. (US) | 2015-03-17 | — | — | US | disclosed |
| US-20140336185-A1 | NOVEL GLP-1 RECEPTOR STABILIZERS AND MODULATORS | RECEPTOS LLC | 2014-11-13 | — | — | US | disclosed |
| WO-2014164780-A1 | FUSED TETRACYCLIC BROMODOMAIN INHIBITORS | ABBVIE INC. (US) | 2014-10-09 | — | — | WO | disclosed |
| US-20140256710-A1 | BROMODOMAIN INHIBITORS | ABBVIE INC. | 2014-09-11 | — | — | US | disclosed |
| WO-2012166951-A9 | NOVEL GLP-1 RECEPTOR STABILIZERS AND MODULATORS | RECEPTOS, INC. (US) | 2013-02-21 | — | — | WO | disclosed |
| WO-2012166951-A1 | NOVEL GLP-1 RECEPTOR STABILIZERS AND MODULATORS | RECEPTOS, INC. (US) | 2012-12-06 | — | — | WO | disclosed |
| US-20120115863-A1 | COMPOUNDS FOR THE TREATMENT OF CNS DISORDERS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-05-10 | — | — | US | disclosed |
| US-20120115863-A1 | COMPOUNDS FOR THE TREATMENT OF CNS DISORDERS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-05-10 | — | — | US | disclosed |
| WO-2010026214-A1 | PYRAZOLOPYRIMIDINES AND THEIR USE FOR THE TREATMENT OF CNS DISORDERS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260144743-A1 | COMPOUNDS | CACNA1E, TMEM109, CACNA1C | HSD17B10 868/4885GAA 1568/4885NPSR1 925/4885 |
| US-12552770-B2 | Compounds for treating respiratory disease | TMEM109, SCN1A, SLC16A1 | HSD17B10 1812/4885GAA 575/4885NPSR1 2143/4885 |
| US-20140336185-A1 | NOVEL GLP-1 RECEPTOR STABILIZERS AND MODULATORS | GLP1R, GIPR, GHSR | HSD17B10 4277/4885GAA 2240/4885NPSR1 145/4885 |
| US-20150150884-A1 | BROMODOMAIN INHIBITORS | BRD4, BRD3, BRD1 | HSD17B10 2785/4885GAA 3173/4885NPSR1 2124/4885 |
| US-20250340535-A1 | ALLOSTERIC EGFR INHIBITORS AND METHODS OF USE THEREOF | EGFR, ERBB2, ERBB3 | HSD17B10 4296/4885GAA 1723/4885NPSR1 3651/4885 |
| US-20120115863-A1 | COMPOUNDS FOR THE TREATMENT OF CNS DISORDERS | CNR1, CNR2, CHRM5 | HSD17B10 862/4885GAA 2258/4885NPSR1 514/4885 |
| US-20240231222-A1 | PHOTORESIST COMPOSITION AND METHOD OF FABRICATING SEMICONDUCTOR DEVICE | ZKSCAN2, PIN1, CRY1 | HSD17B10 4579/4885GAA 4738/4885NPSR1 1978/4885 |
| US-20250340534-A1 | ALLOSTERIC EGFR INHIBITORS AND METHODS OF USE THEREOF | EGFR, ERBB2, ERBB3 | HSD17B10 4296/4885GAA 1723/4885NPSR1 3651/4885 |
| US-20240109899-A1 | BENZOFURAN COMPOUNDS AS STING AGONISTS | STING1, MAVS, IRF3 | HSD17B10 3086/4885GAA 278/4885NPSR1 1029/4885 |
| US-20140256710-A1 | BROMODOMAIN INHIBITORS | BRD4, BRD3, BRD1 | HSD17B10 2785/4885GAA 3173/4885NPSR1 2124/4885 |
| US-20240391877-A1 | COMPOUND AS INHIBITOR OF COMPLEMENT FACTOR D, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | CFD, CFH, C9 | HSD17B10 2436/4885GAA 2605/4885NPSR1 3456/4885 |
| US-12377105-B2 | Compounds | CACNA1E, TMEM109, CACNA1A | HSD17B10 2273/4885GAA 1147/4885NPSR1 1331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.